Ann F Mohrbacher, MD

Associate Professor of Clinical Medicine

Medical Director, Autologous Bone Marrow Transplant

Image of Ann F Mohrbacher, MD
Is this your profile? Click to edit


Dr. Mohrbacher, a graduate of Harvard Medical School, is a devoted educator, researcher and medical practitioner. She has several hematology related research interests and activities, including bone marrow transplantation, and has received thousands of dollars in research grants. She has been published in a number of medical journals and has been invited to lecture on topics including Radioimmunotherapy of non-Hodgkin’s lymphoma and B-cell targeted therapy of rheumatoid arthritis. Dr. Mohrbacher is a member of the Southern California Lymphoma Group and currently belongs to a number of university related committees, such as the Post-Graduate Education Committee and the Clinical Investigations Committee.


  • American Society of Clinical Oncology: Career Development Award, 1995
  • Harvard University : A.B. Magna Cum Laude, 1983
  • Harvard University: Scholarship, 1983


  • Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial Clin Cancer Res. 2023 Dec 15; 29(24):5087-5103. . View in PubMed
  • Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study Blood Adv. 2022 02 22; 6(4):1232-1242. . View in PubMed
  • Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy Eur J Cancer. 2021 11; 157:59-62. . View in PubMed
  • The Emergence of Epstein-Barr Virus-Related Diffuse Large B-Cell Lymphoma With Mogamulizumab World J Oncol. 2020 Feb; 11(1):41-43. . View in PubMed
  • Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States JCO Oncol Pract. 2020 10; 16(10):e1169-e1180. . View in PubMed
  • A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry Blood Adv. 2020 01 14; 4(1):181-190. . View in PubMed
  • HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group JAMA Oncol. 2018 Jan 01; 4(1):54-62. . View in PubMed
  • Unrelated HLA mismatched microtransplantation in a patient with refractory secondary acute myeloid leukemia Leuk Res Rep. 2018; 9:18-20. . View in PubMed
  • Asian-variant intravascular large B-cell lymphoma Proc (Bayl Univ Med Cent). 2017 Apr; 30(2):186-189. . View in PubMed
  • Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia Eur J Haematol. 2016 Apr; 96(4):375-80. . View in PubMed
  • A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618. . View in PubMed
  • Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM Blood. 2016 06 09; 127(23):2833-40. . View in PubMed
  • An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia Med Oncol. 2013 Dec; 30(4):744. . View in PubMed
  • A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma Blood. 2012 Jul 19; 120(3):552-9. . View in PubMed
  • Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma J Clin Oncol. 2012 Jun 01; 30(16):1960-5. . View in PubMed
  • Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial Br J Haematol. 2011 Aug; 154(4):533-5. . View in PubMed
  • Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma Cancer Chemother Pharmacol. 2011 Jan; 67(1):57-67. . View in PubMed
  • A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation Epigenetics. 2010 Nov-Dec; 5(8):750-7. . View in PubMed
  • Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus J Clin Pathol. 2007 May; 60(5):562-4. . View in PubMed
  • Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial Cancer. 2006 Feb 15; 106(4):848-58. . View in PubMed
  • B cell non-Hodgkin’s lymphoma: rituximab safety experience Arthritis Res Ther. 2005; 7 Suppl 3:S19-25. . View in PubMed
  • TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities Transfusion. 2003 May; 43(5):641-5. . View in PubMed
  • Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myelomaA phase II International Oncology Study Group study. Cancer. 2002 May 15; 94(10):2645-52. . View in PubMed
  • Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications Blood. 2000 May 01; 95(9):2990-2. . View in PubMed
  • Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab J Clin Oncol. 1999 Jun; 17(6):1851-7. . View in PubMed
  • The influence of patient-related factors on ex vivo retroviral-mediated gene transfer into mobilized peripheral blood myeloid progenitors Hum Gene Ther. 1998 May 01; 9(7):1061-8. . View in PubMed
  • High-dose chemotherapy and autologous bone marrow plus peripheral blood stem cell transplantation for patients with lymphoma or metastatic breast cancer: use of marker genes to investigate hematopoietic reconstitution in adults Hum Gene Ther. 1996 Mar 20; 7(5):669-84. . View in PubMed
  • Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion Blood. 1993 Dec 15; 82(12):3712-20. . View in PubMed
  • Regulation of c-jun gene expression in human T lymphocytes Blood. 1993 Mar 15; 81(6):1540-8. . View in PubMed
  • Role of interleukin 6 in the growth of myeloma-derived cell lines Leuk Res. 1992 Oct; 16(10):951-9. . View in PubMed